Thus, the available guidelines advise the use of non-HDL-C (or ApoB) as a secondary treatment target in high-risk or very high risk patients with mild-to-moderate hypertriglyceridemia [77]. The gene discussed is APOB; the disease is hypertriglyceridemia.